XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUE
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The following table summarizes the disaggregation of revenue by nature:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions2024202320242023
Net product sales$11,483 $10,645 $34,967 $32,610 
Alliance revenues105 138 355 461 
Other revenues
304 183 636 458 
Total Revenues$11,892 $10,966 $35,958 $33,529 

The following table summarizes GTN adjustments:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions2024202320242023
Gross product sales$21,223 $18,648 $61,298 $54,047 
GTN adjustments(a)
Charge-backs and cash discounts(2,967)(2,373)(8,366)(6,743)
Medicaid and Medicare rebates(4,577)(3,730)(11,525)(9,355)
Other rebates, returns, discounts and adjustments(2,196)(1,900)(6,440)(5,339)
Total GTN adjustments(b)
(9,740)(8,003)(26,331)(21,437)
Net product sales$11,483 $10,645 $34,967 $32,610 
(a)    Includes reductions to GTN adjustments for product sales made in prior periods resulting from changes in estimates of $42 million and $103 million for the three and nine months ended September 30, 2024 and $18 million and $116 million for the three and nine months ended September 30, 2023, respectively.
(b)    Includes U.S. GTN adjustments of $8.9 billion and $23.9 billion for the three and nine months ended September 30, 2024 and $7.3 billion and $19.2 billion for the three and nine months ended September 30, 2023, respectively.
The following table summarizes the disaggregation of revenue by product and region:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions2024202320242023
Growth Portfolio
Opdivo$2,360 $2,275 $6,825 $6,622 
Orencia936 925 2,682 2,616 
Yervoy642 579 1,855 1,672 
Reblozyl447 248 1,226 688 
Opdualag233 166 674 437 
Abecma124 93 301 372 
Zeposia147 123 408 301 
Breyanzi224 92 484 263 
Camzyos156 68 379 143 
Sotyktu66 66 163 107 
Augtyro10 — 23 — 
Krazati34 — 87 — 
Other Growth products(a)
433 311 1,093 886 
Total Growth Portfolio
5,812 4,946 16,200 14,107 
Legacy Portfolio
Eliquis3,002 2,705 10,138 9,332 
Revlimid1,412 1,429 4,434 4,647 
Pomalyst/Imnovid898 872 2,722 2,551 
Sprycel290 517 1,088 1,404 
Abraxane253 260 701 757 
Other Legacy products(b)
225 237 675 731 
Total Legacy Portfolio
6,080 6,020 19,758 19,422 
Total Revenues$11,892 $10,966 $35,958 $33,529 
United States$8,232 $7,542 $25,509 $23,298 
International3,389 3,239 9,803 9,716 
Other(c)
271 185 646 515 
Total Revenues$11,892 $10,966 $35,958 $33,529 
(a)    Includes Onureg, Inrebic, Nulojix, Empliciti and royalty revenues.
(b)    Includes other mature brands.
(c)    Other revenues include alliance-related revenues for products not sold by BMS's regional commercial organizations.

Beginning in 2024, Puerto Rico revenues are included in International revenues. Prior period amounts have been reclassified to conform to the current presentation.

Revenue recognized from performance obligations satisfied in prior periods was $238 million and $496 million for the three and nine months ended September 30, 2024 and $114 million and $355 million for the three and nine months ended September 30, 2023, respectively, consisting primarily of royalties for out-licensing arrangements and revised estimates for GTN adjustments related to prior period sales.